About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

MSDC-0602K

Company: Cirius Therapeutics, Inc.
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Completed NCT NCT02784444

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

Not yet reported Cirius Therapeutics, Inc. 392 participants Est. completion 2019-06 43 sites

MASH Other conditions: Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
View official trial listing →
Status unknown NCT NCT03970031

A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH

Not yet reported Cirius Therapeutics, Inc. 1800 participants Est. completion 2024-09

Type 2 diabetesMASH Other conditions: Non-Alcoholic Fatty Liver Disease
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT03970031

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.